Rapid identification of Fluconazole resistance using Chrom agar Candida

Indian Journal of Pathology and Microbiology

Volumn 44, Issue 3, 2001, Pages 305-307

  Verghese, Susan L ^a   Padmaja, P ^a   Sutha, P ^a   Mathew, T ^a   Johni, Elizabeth Sorna ^a  

^a INSTITUTE OF CARDIOVASCULAR DISEASES   (India)

Author keywords

Candida specise; Chrom agar Candida; Fluconazole resistance

Indexed keywords

FLUCONAZOLE;

AGAR MEDIUM; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA TROPICALIS; DRUG RESISTANCE; FUNGUS CULTURE; GEOTRICHUM CANDIDUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STRAIN DIFFERENCE;

AGAR; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0035712289     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD and Gallant JE. Infection due to fluconazole resistant Candida in patients with AIDS: prevalence and microbiology. Clin. Infect. Dis. 24: 28-34, 1997.
2. Martins MD, Lozano Chiu M and Rex JH. Point prevalence of oropharyngeal carriage of fluconazole resistant candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis. 25: 843-846, 1997.
3. Patterson TF, Revankar SG, Kirkpatrick WR, etal. Simple method for detecting Fluconazole Resistant Yeasts with Chromogenic agar. J. of Clin. Microbiol. 34(7): 1794-1797, 1996.
4. Barchiesi F, Colombo AL, McGough DA, Rinaldi MG. Comparative study of broth macrodilution and microdilution techiques for in vitro antifungal susceptibility testing of yeasts by usingd the National Committee for Clinical laboratory Standard's proposed standard. J. Clin. Microbiol. 32: 2494-2500, 1994.
5. Pfaller MA. Nosocomial candidiasis: emerging species, reserviors and modes of transmission. Clin. Infect. Dis. 22(2): 889-894, 1996.
6. Mahayni R, Vazquez JA, Zarvos MJ. Nosocomial candidiasis: epidemiology and drug resistance. Infectious. Agents and Disease. 4(4): 248-53, 1995.
7. Walsh TJ and Lee JW. Prevention of invasive fungal infections in patients with neoplastic disease. Clin. Infect. Disease. 17(2): 468-480, 1993.
8. Rex JH, Rinaldi MG and Pfaller MA. Resistance of Candida species to Fluconazole. Antimicrob. Agents. Chemother. 39: 1-8, 1995.
9. White TC, Marr KA & Bowden RA. Clinical, Cellular and Molecular factors that contribute to Antifungal drug resistance. Clinical Microbiol Reviews. 2(2): 328-402, 1998.
10. Goff DA, Koletar SL, Buesching WJ, Barnishan J and Fass RJ. Isolation of fluconazole resistant Candida albicans from human immunodificiency virus negative patients never treated with azoles. Clin. Infect. Dis. 20: 77-83, 1995.
11. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MG, Denning DW. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J. Antimicrob. Chemoter. 34(5): 659-68, 1994.
12. Metzger S, Jager H, Hofmann H. Fluconazole sensitivity of Candida strains in invitro in the microdilution test and agar diffusion test. Mycoses-37(1): 46-70, 1994.
13. Sandven P, Bjorneklett A, Maeland A. Susceptibilities of Norwegian Candida albicans strains to flucoanzole : emergence of resistance. The Norwegian Yeast Study Group. Antimicrob. Agents. Chemoter. 37(11): 2443-8, 1993.
14. Price MF, LaRocco MT and Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood culture over a 5 year period. Antimicrob. Agents Chemoter. 38: 1422-1424, 1994.